We invite you to engage in an interactive roundtable led by EverythingALS consortia with over 10 Pharma partners, numerous digital biomarker sensor companies, neurologists, data scientists, regulators and patients to help advance the discovery and implementation of ALS digital biomarkers in clinical trials through our collaborative efforts.
Joining our participatory roundtable, you will be the first to learn about our latest study results on ALS digital biomarkers as well as have the opportunity to hear why major pharmaceutical companies have joined the consortium to partner in our research, which will be expanded to include analyzing data from wearables and smartphones.
As always, we approach each roundtable to encourage out-of-the-box thinking, and to kick it off, we have an exciting agenda! Take a look below.
This is an invite only event.
March 13, 2023 - 1PM ET I 10AM PT
2:00 pm -2:30 pm ET is a Closed session for Consortia Members only
Welcome and Consortia Updates
Indu Navar - CEO and Founder, EverythingALS
James Berry, MD - Neurologist at MGH
Keynote Panel : Women Tell All, Persons Living with ALS
Critical Path (C-PATH) Update for ALS (CP - RND)
Collin Hovinga - PharmD, MS, FCCP
Scientific deep dive : EverythingALS's Radcliff precision medicine digital biomarker research on speech, gait and respiratory functions
Screening for ALS through interactions with an internet search engine: Results of our pilot study - Microsoft Research
Open dialogue and next steps